Ovarian cancer remains one of the deadliest gynecological cancers, particularly because most patients develop resistance to standard treatment. A promising new clinical trial PROTA combines an engineered oncolytic virus TILT-123 with immunotherapy to help the patient's own immune system fight the cancer. This research project will use cutting-edge technologies to study how antibodies and immune cells respond to this innovative treatment. By analyzing patient samples collected throughout the trial, we aim to understand why some patients respond better than others and how the treatment affects the immune system within the tumor. This knowledge could help identify which patients are most likely to benefit from the treatment, develop blood tests to monitor treatment effectiveness, and potentially suggest ways to make the therapy work better for more patients. The insights gained could improve treatment strategies not only for ovarian cancer but for other difficult-to-treat cancers as well.

2025

2029